Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) has provided an update.
JW (Cayman) Therapeutics Co. Ltd. reported a 22.5% increase in revenue to RMB106.3 million for the first half of 2025, driven by sales of Carteyva® and licensing income. Despite a loss of RMB267.3 million due to an impairment charge, the company improved its operational efficiency, reducing selling, general, and R&D expenses, which led to a decrease in recurring operating loss by RMB126.5 million compared to the previous year.
The most recent analyst rating on (HK:2126) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is a company incorporated in the Cayman Islands, operating in the biotechnology sector. It focuses on the commercialization of innovative therapies, with products like Carteyva® and licensing agreements such as the non-exclusive license granted to Juno under the JW sLVV Manufacturing Process.
Average Trading Volume: 5,149,250
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.51B
For a thorough assessment of 2126 stock, go to TipRanks’ Stock Analysis page.